Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRG | P62508 | 1/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.48 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.48 |
| ▸ | MAOB | P27338 | 5/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4896887 | 0.89 | HDAC3 (0.56) | ROCK2ROCK1PPARAHSD17B2MAOB | |
| SCHEMBL12788248 | 0.80 | PPARA (0.69) | ESRRGPPARAPTPN1HDAC3HDAC4 | |
| SCHEMBL4896946 | 0.75 | SRC (0.57) | ESRRGROCK2ROCK1MAOBSRC | |
| SCHEMBL8244269 | 0.73 | KMT2A (0.60) | ESRRGROCK2ROCK1SRCDYRK1A | |
| SCHEMBL18906063 | 0.72 | HPGD (0.59) | ROCK2ROCK1SRC | |
| SCHEMBL10066965 | 0.72 | F10 (0.53) | ROCK2ROCK1PPARA | |
| SCHEMBL10066502 | 0.72 | ROCK2 (0.61) | ROCK2ROCK1PPARA | |
| SCHEMBL4893495 | 0.71 | ALDH1A1 (0.61) | ESRRGROCK2ROCK1SRCPTPN1 | |
| SCHEMBL5041568 | 0.71 | SMN1; SMN2 (0.54) | HSD17B1HSD17B2PTPN1HDAC1HDAC6 | |
| SCHEMBL12496876 | 0.71 | HSD17B1 (0.65) | ESRRGROCK2ROCK1HSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | MERCK PATENT GMBH (DE) | 2008-04-17 | — | — | US | claimed |
| US-8815924-B2 | Heterocyclic carbonyl compounds | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-8815924-B2 | Heterocyclic carbonyl compounds | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-8815924-B2 | Heterocyclic carbonyl compounds | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | MERCK PATENT GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | MERCK PATENT GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | MERCK PATENT GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | SGK1, SGK2, SGK3 | ESRRG 2267/4885ROCK2 1337/4885ROCK1 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.